- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-UBE2D2 monoclonal antibody
Pre-made anti-UBE2D2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to UBE2D2/UBE2D2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP2796-Ab-1/ GM-Tg-hg-IP2796-Ab-2 | Anti-Human UBE2D2 monoclonal antibody | Human |
| GM-Tg-rg-IP2796-Ab-1/ GM-Tg-rg-IP2796-Ab-2 | Anti-Rat UBE2D2 monoclonal antibody | Rat |
| GM-Tg-mg-IP2796-Ab-1/ GM-Tg-mg-IP2796-Ab-2 | Anti-Mouse UBE2D2 monoclonal antibody | Mouse |
| GM-Tg-cynog-IP2796-Ab-1/ GM-Tg-cynog-IP2796-Ab-2 | Anti-Cynomolgus/ Rhesus macaque UBE2D2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP2796-Ab-1/ GM-Tg-felg-IP2796-Ab-2 | Anti-Feline UBE2D2 monoclonal antibody | Feline |
| GM-Tg-cang-IP2796-Ab-1/ GM-Tg-cang-IP2796-Ab-2 | Anti-Canine UBE2D2 monoclonal antibody | Canine |
| GM-Tg-bovg-IP2796-Ab-1/ GM-Tg-bovg-IP2796-Ab-2 | Anti-Bovine UBE2D2 monoclonal antibody | Bovine |
| GM-Tg-equg-IP2796-Ab-1/ GM-Tg-equg-IP2796-Ab-2 | Anti-Equine UBE2D2 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-IP2796-Ab-1/ GM-Tg-hg-IP2796-Ab-2; GM-Tg-rg-IP2796-Ab-1/ GM-Tg-rg-IP2796-Ab-2; GM-Tg-mg-IP2796-Ab-1/ GM-Tg-mg-IP2796-Ab-2; GM-Tg-cynog-IP2796-Ab-1/ GM-Tg-cynog-IP2796-Ab-2; GM-Tg-felg-IP2796-Ab-1/ GM-Tg-felg-IP2796-Ab-2; GM-Tg-cang-IP2796-Ab-1/ GM-Tg-cang-IP2796-Ab-2; GM-Tg-bovg-IP2796-Ab-1/ GM-Tg-bovg-IP2796-Ab-2; GM-Tg-equg-IP2796-Ab-1/ GM-Tg-equg-IP2796-Ab-2 |
| Products Name | Anti-UBE2D2 monoclonal antibody |
| Format | mab |
| Target Name | UBE2D2 |
| Protein Sub-location | Introcelluar Protein |
| Category of antibody | |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
| Tag | Fc |
| Products description | Pre-made anti-UBE2D2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-IP2796-Ag-1 | Recombinant multi-species UB2D2/ UBE2D2/ E2(17)KB2 protein |
| ORF Viral Vector | pGMLP004533 | human UBE2D2 Lentivirus plasmid |
| ORF Viral Vector | vGMLP004533 | human UBE2D2 Lentivirus particle |
| ORF Viral Vector | pGMLPm002373 | mouse Ube2d2a Lentivirus plasmid |
| ORF Viral Vector | vGMLPm002373 | mouse Ube2d2a Lentivirus particle |
Target information
| Target ID | GM-IP2796 |
| Target Name | UBE2D2 |
| Gene ID | 7322,56550,641452,694667,612742,101092081,541003,100630045 |
| Gene Symbol and Synonyms | 1500034D03Rik,E2(17)KB2,E217kB,PUBC1,Ubc2e,UBC4,UBC4/5,UBCH4,UBCH5B,UBE2D2,Ube2d2a |
| Uniprot Accession | P62837,P62839,Q1RMX2 |
| Uniprot Entry Name | UB2D2_HUMAN,UB2D2_RAT,UB2D2_BOVIN |
| Protein Sub-location | Introcelluar Protein |
| Category | |
| Disease | Prostate Cancer |
| Gene Ensembl | ENSG00000131508 |
| Target Classification | N/A |
The target: UBE2D2, gene name: UBE2D2, also named as E2(17)KB2, PUBC1, UBC4, UBC4/5, UBCH4, UBCH5B. Regulated degradation of misfolded, damaged or short-lived proteins in eukaryotes occurs via the ubiquitin (Ub)-proteasome system (UPS). An integral part of the UPS system is the ubiquitination of target proteins and covalent linkage of Ub-containing proteins to form polymeric chains, marking them as targets for 26S proteasome-mediated degradation. Ubiquitination of proteins is mediated by a cascade of enzymes which includes E1 (ubiquitin activating), E2 (ubiquitin conjugating), and E3 (ubiquitin ligases) enzymes. This gene encodes a member of the E2 enzyme family. Substrates of this enzyme include the tumor suppressor protein p53 and peroxisomal biogenesis factor 5 (PEX5). Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, May 2013].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
